ADIA Injects $200 Million into India's Meril Life Sciences, Valuing MedTech Firm at $6.6 Billion.

A wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has finalized agreements to invest $200 million for a 3 percent stake in the Indian medical devices firm, Meril Life Sciences. This significant investment places Meril Life Sciences' valuation at an impressive $6.6 billion.

This strategic infusion of capital means Meril will now be backed by two major global investors: ADIA and Warburg Pincus, which had previously invested in the company.

Founded by the Bilakhia Group, Meril Life Sciences has established itself as a global innovator in medical technology (MedTech). The company is renowned for its strong emphasis on clinically advanced solutions across a diverse range of medical specialties. These include Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics, and Surgical Robotics, showcasing Meril's broad impact on healthcare innovation.